# Editorial: Advancements in drug development: exploring bi-specific antibodies as promising therapeutic strategies in oncology

**Authors:** Urs M. Weber, Julie M. Bailis, Angela Coxon, Sharon R. Pine, Giuseppe Giaccone

PMC · DOI: 10.3389/fonc.2025.1651944 · Frontiers in Oncology · 2025-07-08

## Full-text entities

- **Genes:** TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}, CD274 (CD274 molecule) [NCBI Gene 29126] {aka ADMIO5, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1}, Cd28 (CD28 antigen) [NCBI Gene 12487], TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, SPATA2 (spermatogenesis associated 2) [NCBI Gene 9825] {aka PD1, PPP1R145, tamo}
- **Diseases:** CRS (MESH:D000080424), cancer (MESH:D009369), B-cell malignancies (MESH:D016393), hematologic malignancies (MESH:D019337)
- **Chemicals:** 4-1BB (-), blinatumomab (MESH:C510808)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12279519/full.md

---
Source: https://tomesphere.com/paper/PMC12279519